Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 110

1.

Impact of combination therapy with anti-PD-1 blockade and a STAT3 inhibitor on the tumor-infiltrating lymphocyte status.

Ashizawa T, Iizuka A, Maeda C, Tanaka E, Kondou R, Miyata H, Sugino T, Kawata T, Deguchi S, Mitsuya K, Hayashi N, Asai A, Ito M, Yamaguchi K, Akiyama Y.

Immunol Lett. 2019 Dec;216:43-50. doi: 10.1016/j.imlet.2019.10.003. Epub 2019 Oct 3.

2.

Pretreatment intratumoral susceptibility signals correlate with response to high-dose methotrexate and progression-free survival in primary central nervous system lymphoma.

Deguchi S, Nakashima K, Muramatsu K, Mitsuya K, Oishi T, Shirata K, Hayashi N, Sugino T, Endo M, Nakasu Y.

J Clin Neurosci. 2019 Nov;69:43-50. doi: 10.1016/j.jocn.2019.08.039. Epub 2019 Aug 16.

PMID:
31427235
3.

Identification of a neoantigen epitope in a melanoma patient with good response to anti-PD-1 antibody therapy.

Nonomura C, Otsuka M, Kondou R, Iizuka A, Miyata H, Ashizawa T, Sakura N, Yoshikawa S, Kiyohara Y, Ohshima K, Urakami K, Nagashima T, Ohnami S, Kusuhara M, Mitsuya K, Hayashi N, Nakasu Y, Mochizuki T, Yamaguchi K, Akiyama Y.

Immunol Lett. 2019 Apr;208:52-59. doi: 10.1016/j.imlet.2019.02.004. Epub 2019 Mar 14.

4.

Optimal Sequence of Local and EGFR-TKI Therapy for EGFR-Mutant Non-Small Cell Lung Cancer With Brain Metastases Stratified by Number of Brain Metastases.

Miyawaki E, Kenmotsu H, Mori K, Harada H, Mitsuya K, Mamesaya N, Kawamura T, Kobayashi H, Nakashima K, Omori S, Wakuda K, Ono A, Naito T, Murakami H, Endo M, Nakasu Y, Gon Y, Takahashi T.

Int J Radiat Oncol Biol Phys. 2019 Jul 1;104(3):604-613. doi: 10.1016/j.ijrobp.2019.02.051. Epub 2019 Mar 6.

PMID:
30851347
5.

A T-cell-engaging B7-H4/CD3-bispecific Fab-scFv Antibody Targets Human Breast Cancer.

Iizuka A, Nonomura C, Ashizawa T, Kondou R, Ohshima K, Sugino T, Mitsuya K, Hayashi N, Nakasu Y, Maruyama K, Yamaguchi K, Akiyama Y.

Clin Cancer Res. 2019 May 1;25(9):2925-2934. doi: 10.1158/1078-0432.CCR-17-3123. Epub 2019 Feb 8.

PMID:
30737243
6.

Palliative cerebrospinal fluid shunting for leptomeningeal metastasis-related hydrocephalus in patients with lung adenocarcinoma: A single-center retrospective study.

Mitsuya K, Nakasu Y, Hayashi N, Deguchi S, Takahashi T, Murakami H, Naito T, Kenmotsu H, Ono A, Wakuda K, Harada H.

PLoS One. 2019 Jan 10;14(1):e0210074. doi: 10.1371/journal.pone.0210074. eCollection 2019.

7.

[Classification of Clinical Syndromes Associated with Skull-Base Metastasis in the MR Era].

Hayashi N, Mitsuya K, Deguchi S, Nakasu Y.

No Shinkei Geka. 2018 Oct;46(10):865-873. doi: 10.11477/mf.1436203829. Japanese.

PMID:
30369488
8.

[Surgical Resection of Metastatic Brain Tumors:Risk of Local Recurrence and Leptomeningeal Dissemination, and Implications for Individualized Treatment].

Nakasu Y, Mitsuya K, Deguchi S, Hayashi N, Harada H.

No Shinkei Geka. 2018 Mar;46(3):185-195. doi: 10.11477/mf.1436203703. Japanese.

PMID:
29567868
9.

Posterior reversible encephalopathy syndrome (PRES) induced by pazopanib, a multi-targeting tyrosine kinase inhibitor, in a patient with soft-tissue sarcoma: case report and review of the literature.

Deguchi S, Mitsuya K, Nakasu Y, Hayashi N, Katagiri H, Murata H, Wasa J, Takahashi M, Endo M.

Invest New Drugs. 2018 Apr;36(2):346-349. doi: 10.1007/s10637-017-0521-5. Epub 2017 Oct 25. Review.

10.

Alterations in the placental methylome with maternal obesity and evidence for metabolic regulation.

Mitsuya K, Parker AN, Liu L, Ruan J, Vissers MCM, Myatt L.

PLoS One. 2017 Oct 18;12(10):e0186115. doi: 10.1371/journal.pone.0186115. eCollection 2017.

11.

Negative impact of leukoaraiosis on the incidence of brain metastases in patients with lung cancer.

Hayashi N, Mitsuya K, Nakasu Y, Naito T, Ohka F, Takahashi T.

J Neurooncol. 2017 Nov;135(2):299-306. doi: 10.1007/s11060-017-2574-x. Epub 2017 Jul 27.

12.

Surgical Site Infection after Malignant Brain Tumor Resection: A Multicenter Study for Induction of a Basic Care Bundle.

Uzuka T, Takahashi H, Nakasu Y, Okuda T, Mitsuya K, Hayashi N, Hirose T, Kurai H.

Neurol Med Chir (Tokyo). 2017 Oct 15;57(10):542-547. doi: 10.2176/nmc.oa.2017-0034. Epub 2017 Jul 26.

13.

The anti-tumor activity of the STAT3 inhibitor STX-0119 occurs via promotion of tumor-infiltrating lymphocyte accumulation in temozolomide-resistant glioblastoma cell line.

Akiyama Y, Nonomura C, Ashizawa T, Iizuka A, Kondou R, Miyata H, Sugino T, Mitsuya K, Hayashi N, Nakasu Y, Asai A, Ito M, Kiyohara Y, Yamaguchi K.

Immunol Lett. 2017 Oct;190:20-25. doi: 10.1016/j.imlet.2017.07.005. Epub 2017 Jul 15.

PMID:
28716484
14.

A nationwide multi-institutional retrospective study to identify prognostic factors and develop a graded prognostic assessment system for patients with brain metastases from uterine corpus and cervical cancer.

Hayashi N, Takahashi H, Hasegawa Y, Higuchi F, Takahashi M, Makino K, Takagaki M, Akimoto J, Okuda T, Okita Y, Mitsuya K, Hirashima Y, Narita Y, Nakasu Y; Committee of Brain Tumor Registry of Japan Supported by the Japan Neurosurgical Society.

BMC Cancer. 2017 Jun 2;17(1):397. doi: 10.1186/s12885-017-3358-6.

15.

[Cotton-Dam Wash Cytology:A Technique for Diagnosis and Prevention of Dissemination during Resection of Metastatic Brain Tumors].

Mitsuya K, Nakasu Y, Ono S, Hayashi N, Watanabe R, Ito I.

No Shinkei Geka. 2017 Jan;45(1):29-32. doi: 10.11477/mf.1436203443. Japanese.

PMID:
28100859
16.

Brain metastasis in patients with metastatic breast cancer in the real world: a single-institution, retrospective review of 12-year follow-up.

Matsuo S, Watanabe J, Mitsuya K, Hayashi N, Nakasu Y, Hayashi M.

Breast Cancer Res Treat. 2017 Feb;162(1):169-179. doi: 10.1007/s10549-017-4107-x. Epub 2017 Jan 13.

PMID:
28084583
17.

Combination of a STAT3 Inhibitor and an mTOR Inhibitor Against a Temozolomide-resistant Glioblastoma Cell Line.

Miyata H, Ashizawa T, Iizuka A, Kondou R, Nonomura C, Sugino T, Urakami K, Asai A, Hayashi N, Mitsuya K, Nakasu Y, Yamaguchi K, Akiyama Y.

Cancer Genomics Proteomics. 2017 Jan 2;14(1):83-91.

18.

Elevated preoperative neutrophil-to-lymphocyte ratio as a predictor of worse survival after resection in patients with brain metastasis.

Mitsuya K, Nakasu Y, Kurakane T, Hayashi N, Harada H, Nozaki K.

J Neurosurg. 2017 Aug;127(2):433-437. doi: 10.3171/2016.8.JNS16899. Epub 2016 Dec 2.

PMID:
27911233
19.

[Update Knowledge for Brain Tumors(11)Metastatic Brain Tumors].

Nakasu Y, Mitsuya K, Hayashi N.

No Shinkei Geka. 2016 Oct;44(10):881-895. Japanese. No abstract available.

PMID:
27729610
20.

Immunological effects of the anti-programmed death-1 antibody on human peripheral blood mononuclear cells.

Akiyama Y, Nonomura C, Kondou R, Miyata H, Ashizawa T, Maeda C, Mitsuya K, Hayashi N, Nakasu Y, Yamaguchi K.

Int J Oncol. 2016 Sep;49(3):1099-107. doi: 10.3892/ijo.2016.3586. Epub 2016 Jun 29.

PMID:
27573705
21.

Antitumor Effect of Programmed Death-1 (PD-1) Blockade in Humanized the NOG-MHC Double Knockout Mouse.

Ashizawa T, Iizuka A, Nonomura C, Kondou R, Maeda C, Miyata H, Sugino T, Mitsuya K, Hayashi N, Nakasu Y, Maruyama K, Yamaguchi K, Katano I, Ito M, Akiyama Y.

Clin Cancer Res. 2017 Jan 1;23(1):149-158. doi: 10.1158/1078-0432.CCR-16-0122. Epub 2016 Jul 25.

22.

Expansive hematoma in delayed cerebral radiation necrosis in patients treated with T-DM1: a report of two cases.

Mitsuya K, Watanabe J, Nakasu Y, Hayashi N, Harada H, Ito I.

BMC Cancer. 2016 Jul 4;16:391. doi: 10.1186/s12885-016-2464-1.

23.

[Leptomeningeal Dissemination in Patients with Pituitary Metastasis from Breast Cancer].

Hayashi N, Mitsuya K, Harada H, Watanabe J, Nishimura T, Nakasu Y.

No Shinkei Geka. 2016 May;44(5):371-6. doi: 10.11477/mf.1436203293. Japanese.

PMID:
27166841
24.

Response-adapted treatment with upfront high-dose chemotherapy followed by autologous stem-cell transplantation rescue or consolidation phase high-dose methotrexate for primary central nervous system lymphoma: a long-term mono-center study.

Nakasu Y, Mitsuya K, Hayashi N, Okamura I, Mori K, Enami T, Tatara R, Nakasu S, Ikeda T.

Springerplus. 2016 Mar 10;5:307. doi: 10.1186/s40064-016-1954-6. eCollection 2016.

25.

[Two Surgical Techniques for Metastatic Brain Tumors:Minimum Resection and Removal with Safety Margin].

Nakasu Y, Mitsuya K, Hayashi N, Ito I.

No Shinkei Geka. 2016 Mar;44(3):221-6. doi: 10.11477/mf.1436203260. Japanese.

PMID:
26965063
26.

[Posterior Reversible Encephalopathy Syndrome Associated with Cancer Therapy].

Mitsuya K, Nakasu Y, Hayashi N, Yasui H, Ikeda T, Kuji S, Onozawa Y, Endo M.

No Shinkei Geka. 2016 Mar;44(3):211-9. doi: 10.11477/mf.1436203259. Japanese.

PMID:
26965062
27.

"Comet tail sign": A pitfall of post-gadolinium magnetic resonance imaging findings for metastatic brain tumors.

Mitsuya K, Nakasu Y, Narita Y, Nakasu S, Ohno M, Miyakita Y, Abe M, Ito I, Hayashi N, Endo M.

J Neurooncol. 2016 May;127(3):589-95. doi: 10.1007/s11060-016-2069-1. Epub 2016 Feb 2.

28.

G-Quadruplex DNA- and RNA-Specific-Binding Proteins Engineered from the RGG Domain of TLS/FUS.

Takahama K, Miyawaki A, Shitara T, Mitsuya K, Morikawa M, Hagihara M, Kino K, Yamamoto A, Oyoshi T.

ACS Chem Biol. 2015 Nov 20;10(11):2564-9. doi: 10.1021/acschembio.5b00566. Epub 2015 Sep 21.

PMID:
26360301
29.

Metastatic brain tumors from small-cell esophageal cancer: clinical characteristics and outcome.

Feng W, Harada H, Zhang P, Mitsuya K, Zheng X, Yasui H, Nakasu Y, Chen M, Nishimura T.

J Cancer Res Ther. 2014 Dec;10 Suppl:256-8. doi: 10.4103/0973-1482.151469.

30.

A novel graft material for preventing cerebrospinal fluid leakage in skull base reconstruction: technical note of perifascial areolar tissue.

Hayashi N, Mitsuya K, Gorai K, Inoue K, Ito I, Nakagawa M, Nakasu Y.

J Neurol Surg B Skull Base. 2015 Feb;76(1):7-11. doi: 10.1055/s-0034-1386655. Epub 2014 Aug 11.

31.

Brain metastasis from hepatocellular carcinoma: The impact of radiotherapy on control of intracranial hemorrhage.

Yamakawa Y, Moriguchi M, Aramaki T, Mitsuya K, Asakura K, Sawada A, Endo M, Nakasu Y.

Hepatol Res. 2015 Nov;45(11):1071-5. doi: 10.1111/hepr.12457. Epub 2015 Jan 8.

PMID:
25470452
32.

YKL-40 downregulation is a key factor to overcome temozolomide resistance in a glioblastoma cell line.

Akiyama Y, Ashizawa T, Komiyama M, Miyata H, Oshita C, Omiya M, Iizuka A, Kume A, Sugino T, Hayashi N, Mitsuya K, Nakasu Y, Yamaguchi K.

Oncol Rep. 2014 Jul;32(1):159-66. doi: 10.3892/or.2014.3195. Epub 2014 May 16.

PMID:
24842123
33.

Effect of the STAT3 inhibitor STX-0119 on the proliferation of a temozolomide-resistant glioblastoma cell line.

Ashizawa T, Akiyama Y, Miyata H, Iizuka A, Komiyama M, Kume A, Omiya M, Sugino T, Asai A, Hayashi N, Mitsuya K, Nakasu Y, Yamaguchi K.

Int J Oncol. 2014 Jul;45(1):411-8. doi: 10.3892/ijo.2014.2439. Epub 2014 May 12.

PMID:
24820265
34.

Novel cancer-testis antigen expression on glioma cell lines derived from high-grade glioma patients.

Akiyama Y, Komiyama M, Miyata H, Yagoto M, Ashizawa T, Iizuka A, Oshita C, Kume A, Nogami M, Ito I, Watanabe R, Sugino T, Mitsuya K, Hayashi N, Nakasu Y, Yamaguchi K.

Oncol Rep. 2014 Apr;31(4):1683-90. doi: 10.3892/or.2014.3049. Epub 2014 Feb 24.

PMID:
24573400
35.

Epigenetics of human myometrium: DNA methylation of genes encoding contraction-associated proteins in term and preterm labor.

Mitsuya K, Singh N, Sooranna SR, Johnson MR, Myatt L.

Biol Reprod. 2014 May 8;90(5):98. doi: 10.1095/biolreprod.113.113209. Print 2014 May.

PMID:
24571989
36.

Anti-vascular endothelial growth factor receptor (VEGFR) 2 autoantibody identification in glioblastoma patient using single B cell-based antibody gene cloning.

Iizuka A, Komiyama M, Oshita C, Kume A, Ashizawa T, Mitsuya K, Hayashi N, Nakasu Y, Yamaguchi K, Akiyama Y.

Immunol Lett. 2014 May-Jun;159(1-2):15-22. doi: 10.1016/j.imlet.2014.02.004. Epub 2014 Feb 15.

PMID:
24534640
37.

[Metastatic brain tumors from gastrointestinal cancer: an analysis of patient background and treatment results].

Mizokami Y, Mitsuya K, Hayashi N, Yasui H, Harada H, Nishimura T, Nakasu Y.

No Shinkei Geka. 2013 Aug;41(8):669-77. Review. Japanese.

PMID:
23907473
38.
39.

Effect of the STAT3 inhibitor STX-0119 on the proliferation of cancer stem-like cells derived from recurrent glioblastoma.

Ashizawa T, Miyata H, Iizuka A, Komiyama M, Oshita C, Kume A, Nogami M, Yagoto M, Ito I, Oishi T, Watanabe R, Mitsuya K, Matsuno K, Furuya T, Okawara T, Otsuka M, Ogo N, Asai A, Nakasu Y, Yamaguchi K, Akiyama Y.

Int J Oncol. 2013 Jul;43(1):219-27. doi: 10.3892/ijo.2013.1916. Epub 2013 Apr 23.

PMID:
23612755
40.

α-type-1 polarized dendritic cell-based vaccination in recurrent high-grade glioma: a phase I clinical trial.

Akiyama Y, Oshita C, Kume A, Iizuka A, Miyata H, Komiyama M, Ashizawa T, Yagoto M, Abe Y, Mitsuya K, Watanabe R, Sugino T, Yamaguchi K, Nakasu Y.

BMC Cancer. 2012 Dec 27;12:623. doi: 10.1186/1471-2407-12-623.

41.

[Multidisciplinary treatment of leptomeningeal metastasis in patients with lung adenocarcinoma: the triple modality combination of EGFR-TKI, VP shunt and irradiation].

Mitsuya K, Nakasu Y, Mizokami Y, Takahashi T, Nakamura Y, Ono A, Toda Y, Yamamoto N, Harada H, Nishimura T.

No Shinkei Geka. 2012 Jun;40(6):503-9. Japanese.

PMID:
22647509
42.

Prognostic factors and clinical outcome of patients with lung adenocarcinoma with carcinomatous meningitis.

Nakamura Y, Takahashi T, Tsuya A, Naito T, Kenmotsu H, Ono A, Shukuya T, Murakami H, Harada H, Watanabe R, Endo M, Mitsuya K, Nakajima T, Yamamoto N.

Anticancer Res. 2012 May;32(5):1811-6.

PMID:
22593466
43.

Feasibility of proton beam therapy for chordoma and chondrosarcoma of the skull base.

Fuji H, Nakasu Y, Ishida Y, Horiguchi S, Mitsuya K, Kashiwagi H, Murayama S.

Skull Base. 2011 May;21(3):201-6. doi: 10.1055/s-0031-1275636.

44.

Leptomeningeal carcinomatosis associated with gastric cancer.

Tomita H, Yasui H, Boku N, Nakasu Y, Mitsuya K, Onozawa Y, Fukutomi A, Yamazaki K, Machida N, Taku K, Todaka A, Taniguchi H, Tsushima T.

Int J Clin Oncol. 2012 Aug;17(4):361-6. doi: 10.1007/s10147-011-0301-8. Epub 2011 Aug 17.

PMID:
21847535
45.

Continuous EGFR-TKI administration following radiotherapy for non-small cell lung cancer patients with isolated CNS failure.

Shukuya T, Takahashi T, Naito T, Kaira R, Ono A, Nakamura Y, Tsuya A, Kenmotsu H, Murakami H, Harada H, Mitsuya K, Endo M, Nakasu Y, Takahashi K, Yamamoto N.

Lung Cancer. 2011 Dec;74(3):457-61. doi: 10.1016/j.lungcan.2011.04.007. Epub 2011 May 14.

PMID:
21571388
46.

Role for piRNAs and noncoding RNA in de novo DNA methylation of the imprinted mouse Rasgrf1 locus.

Watanabe T, Tomizawa S, Mitsuya K, Totoki Y, Yamamoto Y, Kuramochi-Miyagawa S, Iida N, Hoki Y, Murphy PJ, Toyoda A, Gotoh K, Hiura H, Arima T, Fujiyama A, Sado T, Shibata T, Nakano T, Lin H, Ichiyanagi K, Soloway PD, Sasaki H.

Science. 2011 May 13;332(6031):848-52. doi: 10.1126/science.1203919.

47.

Pleomorphic xanthoastrocytoma and moyamoya disease in a patient with neurofibromatosis type 1 - case report - .

Horiguchi S, Mitsuya K, Watanabe R, Yagishita S, Nakasu Y.

Neurol Med Chir (Tokyo). 2011;51(4):310-4.

48.

O6-methylguanine DNA methyltransferase expression in tumor cells predicts outcome of radiotherapy plus concomitant and adjuvant temozolomide therapy in patients with primary glioblastoma.

Watanabe R, Nakasu Y, Tashiro H, Mitsuya K, Ito I, Nakasu S, Nakajima T.

Brain Tumor Pathol. 2011 Apr;28(2):127-35. doi: 10.1007/s10014-011-0022-8. Epub 2011 Feb 18.

PMID:
21331613
49.

Metastatic skull tumors: MRI features and a new conventional classification.

Mitsuya K, Nakasu Y, Horiguchi S, Harada H, Nishimura T, Yuen S, Asakura K, Endo M.

J Neurooncol. 2011 Aug;104(1):239-45. doi: 10.1007/s11060-010-0465-5. Epub 2010 Nov 26.

50.

Epigenetic modification of fetal baboon hepatic phosphoenolpyruvate carboxykinase following exposure to moderately reduced nutrient availability.

Nijland MJ, Mitsuya K, Li C, Ford S, McDonald TJ, Nathanielsz PW, Cox LA.

J Physiol. 2010 Apr 15;588(Pt 8):1349-59. doi: 10.1113/jphysiol.2009.184168. Epub 2010 Feb 22.

Supplemental Content

Loading ...
Support Center